Inclusion criteria were: (1) grade 2 to 4 gliomas confirmed on histopathology, (2) known IDH mutation, 1p/19q codeletion, and MGMT promoter methylation status, and (3) aged > 18 years. The gene discussed is IDH2; the disease is central nervous system cancer.